1
|
Arnau‐Soler A, Tremblay BL, Sun Y, Madore A, Simard M, Kersten ETG, Ghauri A, Marenholz I, Eiwegger T, Simons E, Chan ES, Nadeau K, Sampath V, Mazer BD, Elliott S, Hampson C, Soller L, Sandford A, Begin P, Hui J, Wilken BF, Gerdts J, Bourkas A, Ellis AK, Vasileva D, Clarke A, Eslami A, Ben‐Shoshan M, Martino D, Daley D, Koppelman GH, Laprise C, Lee Y, Asai Y. Food Allergy Genetics and Epigenetics: A Review of Genome-Wide Association Studies. Allergy 2025; 80:106-131. [PMID: 39698764 PMCID: PMC11724255 DOI: 10.1111/all.16429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Revised: 10/12/2024] [Accepted: 11/26/2024] [Indexed: 12/20/2024]
Abstract
In this review, we provide an overview of food allergy genetics and epigenetics aimed at clinicians and researchers. This includes a brief review of the current understanding of genetic and epigenetic mechanisms, inheritance of food allergy, as well as a discussion of advantages and limitations of the different types of studies in genetic research. We specifically focus on the results of genome-wide association studies in food allergy, which have identified 16 genetic variants that reach genome-wide significance, many of which overlap with other allergic diseases, including asthma, atopic dermatitis, and allergic rhinitis. Identified genes for food allergy are mainly involved in epithelial barrier function (e.g., FLG, SERPINB7) and immune function (e.g., HLA, IL4). Epigenome-wide significant findings at 32 loci are also summarized as well as 14 additional loci with significance at a false discovery of < 1 × 10-4. Integration of epigenetic and genetic data is discussed in the context of disease mechanisms, many of which are shared with other allergic diseases. The potential utility of genetic and epigenetic discoveries is deliberated. In the future, genetic and epigenetic markers may offer ways to predict the presence or absence of clinical IgE-mediated food allergy among sensitized individuals, likelihood of development of natural tolerance, and response to immunotherapy.
Collapse
Affiliation(s)
- Aleix Arnau‐Soler
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu BerlinBerlinGermany
- Experimental and Clinical Research Center, a Joint Cooperation of Max Delbruck Center for Molecular Medicine and Charité—Universitätsmedizin BerlinBerlinGermany
- German Center for Child and Adolescent Health (DZKJ)BerlinGermany
| | - Bénédicte L. Tremblay
- Département Des Sciences FondamentalesUniversité du Québec à ChicoutimiSaguenayQuebecCanada
| | - Yidan Sun
- Department of Pediatric Pulmonology and Pediatric AllergologyUniversity Medical Center Groningen, Beatrix Children's Hospital, University of GroningenGroningenthe Netherlands
- University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)Groningenthe Netherlands
| | - Anne‐Marie Madore
- Département Des Sciences FondamentalesUniversité du Québec à ChicoutimiSaguenayQuebecCanada
| | - Mathieu Simard
- Département Des Sciences FondamentalesUniversité du Québec à ChicoutimiSaguenayQuebecCanada
| | - Elin T. G. Kersten
- Department of Pediatric Pulmonology and Pediatric AllergologyUniversity Medical Center Groningen, Beatrix Children's Hospital, University of GroningenGroningenthe Netherlands
- University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)Groningenthe Netherlands
| | - Ahla Ghauri
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu BerlinBerlinGermany
- Experimental and Clinical Research Center, a Joint Cooperation of Max Delbruck Center for Molecular Medicine and Charité—Universitätsmedizin BerlinBerlinGermany
- German Center for Child and Adolescent Health (DZKJ)BerlinGermany
| | - Ingo Marenholz
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu BerlinBerlinGermany
- Experimental and Clinical Research Center, a Joint Cooperation of Max Delbruck Center for Molecular Medicine and Charité—Universitätsmedizin BerlinBerlinGermany
| | - Thomas Eiwegger
- Translational Medicine Program, Research InstituteHospital for Sick ChildrenTorontoOntarioCanada
- Department of Immunology, Temerty Faculty of MedicineUniversity of TorontoTorontoOntarioCanada
- Karl Landsteiner University of Health SciencesKrems an der DonauAustria
- Department of Pediatric and Adolescent MedicineUniversity Hospital St. PöltenSt. PöltenAustria
- Department of Paediatrics, Division of Clinical Immunology and Allergy, Food Allergy and Anaphylaxis Program, the Hospital for Sick ChildrenThe University of TorontoTorontoOntarioCanada
| | - Elinor Simons
- Section of Allergy & Clinical Immunology, Department of Pediatrics & Child Health, University of ManitobaChildren's Hospital Research InstituteWinnipegManitobaCanada
| | - Edmond S. Chan
- Division of Allergy, Department of PediatricsThe University of British ColumbiaVancouverBritish ColumbiaCanada
| | - Kari Nadeau
- Department of Environmental StudiesHarvard T.H. Chan School of Public HealthBostonMassachusettsUSA
| | - Vanitha Sampath
- Department of Environmental StudiesHarvard T.H. Chan School of Public HealthBostonMassachusettsUSA
| | - Bruce D. Mazer
- Research Institute of the McGill University Health CentreMontrealQuebecCanada
| | - Susan Elliott
- Department of Geography and Environmental ManagementUniversity of WaterlooWaterlooOntarioCanada
| | | | - Lianne Soller
- Division of Allergy, Department of PediatricsThe University of British ColumbiaVancouverBritish ColumbiaCanada
| | - Andrew Sandford
- Department of MedicineThe University of British ColumbiaVancouverBritish ColumbiaCanada
- Centre for Heart Lung InnovationVancouverBritish ColumbiaCanada
| | - Philippe Begin
- Department of Pediatrics, Service of Allergy and Clinical ImmunologyCentre Hospitalier Universitaire Sainte‐JustineMontréalQuébecCanada
- Department of Medicine, Service of Allergy and Clinical ImmunologyCentre Hospitalier de l'Université de MontréalMontréalQuébecCanada
| | - Jennie Hui
- School of Population HealthUniversity of Western AustraliaPerthWestern AustraliaAustralia
| | - Bethany F. Wilken
- School of Medicine, Department of MedicineQueen's UniversityKingstonOntarioCanada
| | | | - Adrienn Bourkas
- School of Medicine, Department of MedicineQueen's UniversityKingstonOntarioCanada
| | - Anne K. Ellis
- Division of Allergy & Immunology, Department of MedicineQueen's UniversityKingstonOntarioCanada
| | - Denitsa Vasileva
- Department of MedicineThe University of British ColumbiaVancouverBritish ColumbiaCanada
- Centre for Heart Lung InnovationVancouverBritish ColumbiaCanada
| | - Ann Clarke
- Department of Medicine, Cumming School of MedicineUniversity of CalgaryCalgaryAlbertaCanada
| | - Aida Eslami
- Département de médecine Sociale et préventive, Faculté de médecineUniversité LavalQuebecCanada
| | - Moshe Ben‐Shoshan
- Division of Allergy and Clinical Immunology, Department of Pediatrics, Montréal Children's HospitalMcGill University Health CentreMontréalQuebecCanada
| | - David Martino
- Wal‐Yan Respiratory Research CentreTelethon Kids InstitutePerthAustralia
| | - Denise Daley
- Department of MedicineThe University of British ColumbiaVancouverBritish ColumbiaCanada
- Centre for Heart Lung InnovationVancouverBritish ColumbiaCanada
| | - Gerard H. Koppelman
- Department of Pediatric Pulmonology and Pediatric AllergologyUniversity Medical Center Groningen, Beatrix Children's Hospital, University of GroningenGroningenthe Netherlands
- University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)Groningenthe Netherlands
| | - Catherine Laprise
- Département Des Sciences FondamentalesUniversité du Québec à ChicoutimiSaguenayQuebecCanada
| | - Young‐Ae Lee
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu BerlinBerlinGermany
- Experimental and Clinical Research Center, a Joint Cooperation of Max Delbruck Center for Molecular Medicine and Charité—Universitätsmedizin BerlinBerlinGermany
- German Center for Child and Adolescent Health (DZKJ)BerlinGermany
| | - Yuka Asai
- Division of Dermatology, Department of MedicineQueen's UniversityKingstonOntarioCanada
| |
Collapse
|
2
|
Zhang P, Ruan C, Yang G, Guan Y, Zhu Y, Li Q, Dai X, An Y, Shi X, Huang P, Chen Y, He Z, Du Z, Liu C. PGRN Inhibits Early B-cell Activation and IgE Production Through the IFITM3-STAT1 Signaling Pathway in Asthma. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024; 11:e2403939. [PMID: 39412083 PMCID: PMC11615816 DOI: 10.1002/advs.202403939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2024] [Revised: 09/23/2024] [Indexed: 12/06/2024]
Abstract
Progranulin (PGRN) plays a critical role in bronchial asthma and the function of various immune cells. However, the mechanisms by which PGRN influences B-cell receptor (BCR) signaling and immunoglobulin E(IgE) production are not fully understood. The study aimed to elucidate the molecular mechanisms through which PGRN affects BCR signaling, B-cell differentiation, and IgE production. A PGRN knockout mouse model, along with techniques including flow cytometry, the creation of a bone marrow chimeric mouse model, total internal reflection fluorescence (TIRF), and Western blot (WB) analysis is employed, to investigate the link between PGRN and various aspects of B-cell biology. It is discovered that the absence of PGRN in mice alters peripheral B-cell subpopulations, promotes IgE class switching in a cell-intrinsic manner, and affects B-cell subpopulations. Additionally, PGRN modulates B-cell functions by regulating BCR signaling pathways, metabolic processes, and the actin cytoskeleton during early B-cell activation. Significantly, PGRN deficiency results in diminished production of NP-specific antibodies. Moreover, it is found that PGRN inhibits B-cell activation and IgE production through the PGRN-IFITM3-STAT1 signaling pathway. The findings provide new strategies for the targeted treatment of bronchial asthma, highlighting the crucial role of PGRN in B-cell signaling and IgE production.
Collapse
Affiliation(s)
- Pingping Zhang
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Changshun Ruan
- Chongqing Key Laboratory of Child Infection and ImmunityChildren's Hospital of Chongqing Medical UniversityChongqing400014China
| | - Guangli Yang
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Yaning Guan
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Yin Zhu
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Qian Li
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Xin Dai
- Zhanjiang Institute of Clinical MedicineZhanjiang Central HospitalGuangdong Medical UniversityZhanjiang524037China
- Department of HematologyCentral People's Hospital of ZhanjiangZhanjiang524037China
| | - Yang An
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Xiaoqi Shi
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Pei Huang
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Yan Chen
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Zhixu He
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Zuochen Du
- Department of PediatricsAffiliated Hospital of Zunyi Medical UniversityZunyi563000China
- Department of PediatricsGuizhou Children's HospitalZunyi563000China
- Collaborative Innovation Center for Tissue Injury Repair and Regenerative Medicine of Zunyi Medical UniversityZunyi563099China
| | - Chaohong Liu
- Department of Pathogen Biology School of Basic MedicineTongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious DiseasesHuazhong University of Science and Technology Wuhan Hubei ChinaHubei430074China
| |
Collapse
|
3
|
Kang YM, Kim HM, Lee M, An HJ. Effects of Echinocystic Acid on Atopic Dermatitis and Allergic Inflammation of the Skin and Lungs. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 104:154211. [PMID: 35717808 DOI: 10.1016/j.phymed.2022.154211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 05/22/2022] [Accepted: 05/25/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Echinocystic acid (ECA), a pentacyclic triterpene enriched in various herbs, promotes anti-inflammatory and antioxidant activity; however, its therapeutic effects on atopic dermatitis (AD) or atopic march and the underlying mechanisms of action have not yet been fully elucidated. PURPOSE This study aimed to elucidate the effects and molecular mechanisms of ECA on AD and allergic inflammation. METHODS We evaluated the inhibitory effects of ECA using a house dust mite (HDM)-induced AD mouse model and human keratinocytes. RESULTS The results revealed that ECA improved AD symptoms by decreasing epidermal/dermal thickness, immune cell infiltration, and restoring skin barrier function, as well as an imbalanced immune response. In addition, repeated epicutaneous HDM challenges aggravated allergic inflammation in mice lungs, which was caused by the infiltration of immune cells and collagen deposition, whereas ECA alleviated these symptoms. Moreover, ECA suppressed the expression of T helper cell-derived cytokines, phosphorylation of extracellular signal-regulated kinase, and signal transducer and activator of transcription 1 in the skin and lungs of mice with HDM-induced AD, as well as inhibited the translocation of nuclear factor-κB in HaCaT keratinocytes. CONCLUSION This is the meaningful study to demonstrate that ECA improves allergic inflammation of the skin and lungs through recovery of the skin barrier, regulation of immune balance, and alleviation of lung inflammation, suggesting that ECA has therapeutic potential as an antiatopic and antiallergic agent that blocks the progression of AD to atopic march.
Collapse
Affiliation(s)
- Yun-Mi Kang
- Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju, Gangwon-do, 26339, Republic of Korea; Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), 70 Cheomdan-ro, Dong-gu, Daegu 41062, Republic of Korea
| | - Hye-Min Kim
- Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju, Gangwon-do, 26339, Republic of Korea
| | - Minho Lee
- Department of Life Science, Dongguk University-Seoul, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10326, Republic of Korea.
| | - Hyo-Jin An
- Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju, Gangwon-do, 26339, Republic of Korea.
| |
Collapse
|
4
|
Wei H, Xu L, Sun P, Xing H, Zhu Z, Liu J. Activation of STAT6 by intranasal allergens correlated with the development of eosinophilic chronic rhinosinusitis in a mouse model. Int J Immunopathol Pharmacol 2022; 36:3946320221109529. [PMID: 35726645 PMCID: PMC9218454 DOI: 10.1177/03946320221109529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Eosinophilic chronic rhinosinusitis (ECRS) is a chronic inflammatory disease characterized by prominent eosinophilic infiltration along with a T-helper-2 (Th2) response. It has been well documented that signal transducer and activator of transcription 6 (STAT6) is a nuclear transcription factor that mediates Th2-type immunity and is implicatory of STAT1 and STAT3 in the pathogenesis of allergic airway diseases. However, little is known about the association between STATs and ECRS. Here, we explored the relationship between STAT1, STAT3, and/or STAT6 and eosinophilic inflammation accompanied by Th2-type immunity in a mouse model of ECRS. An ovalbumin (OVA)-staphylococcal enterotoxin B (SEB)-induced ECRS murine model was first established. The mucosal histological alterations were determined using hematoxylin and eosin staining. The number of eosinophils in peripheral blood was measured using a blood cell analyzer. The cytokine (IL-4, IL-5, IL17 A and IFN-γ) expression levels in the sinonasal mucosa and total and OVA-specific IgE from serum were measured using ELISA. Then, the protein levels of STAT1, STAT3, STAT6, phosphorylated STAT1 (p-STAT1), p-STAT3, p-STAT6, T-box expressed in T-cells (T-bet), GATA binding protein 3 (GATA-3), and retinoic acid receptor-related orphan receptor γ (RORγt) in the sinonasal mucosa were examined by immunohistochemical staining or Western blotting. Local administration of OVA combined with SEB (OVA + SEB) induced multiple polyp-like lesions, accompanied by prominent eosinophilic infiltration in the sinonasal mucosa. The OVA- and OVA+SEB-treated groups showed significantly higher eosinophil counts from peripheral blood and total and OVA-specific IgE levels from serum than those in the PBS- and SEB-treated groups. The levels of p-STAT6 were markedly increased by OVA + SEB exposure, as well as GATA-3, IL-4, and IL-5, but did not affect STAT6, p-STAT1, p-STAT3, T-bet, RORγt, IFN-γ, or IL-17A. Furthermore, an eosinophil count in the sinonasal mucosa showed a positive correlation with the level of p-STAT6 in the ECRS mouse model. Signal transducer and activator of transcription 6 signaling could be activated in the OVA+SEB-induced ECRS model and might be a crucial signal transducer in the development of Th2-skewed ECRS.
Collapse
Affiliation(s)
- Hongqi Wei
- Department of Otorhinolaryngology, 74566The First Affiliated Hospital of Soochow University, Suzhou, China.,Department of Otorhinolaryngology, 105860The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Longjiang Xu
- Department of Pathology, 105860The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Peng Sun
- Department of Otorhinolaryngology, 74566The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Hongyu Xing
- Department of Otorhinolaryngology, 105860The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Zhengwen Zhu
- Department of Otorhinolaryngology, 105860The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Jisheng Liu
- Department of Otorhinolaryngology, 74566The First Affiliated Hospital of Soochow University, Suzhou, China
| |
Collapse
|
5
|
Taurine promotes the production of CD4 +CD25 +FOXP3 + Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model. Allergy Asthma Clin Immunol 2021; 17:59. [PMID: 34147127 PMCID: PMC8214264 DOI: 10.1186/s13223-021-00562-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 06/03/2021] [Indexed: 12/24/2022] Open
Abstract
Background Allergic rhinitis (AR) is one of the most widespread immune conditions worldwide. However, common treatments often present with significant side effects or are cost-prohibitive for much of the population. A plethora of treatments have been used for the treatment of AR including antihistamines, steroids, and immune modulators. Among the treatments which have shown potential for efficacy in treating AR with a minimum of side effects but remains understudied is the conditionally essential amino acid taurine. Taurine has been previously shown to reduce AR symptoms. Here, we examine the role of taurine in modulating T regulatory cells, modulating the cytokine response in AR, and restoring healthy nasal mucosa. Methods Blood samples from 20 healthy donors and 20 AR patients were compared for CD4+CD25+FoxP3+ T regulatory (Treg) cell population percentage, cytokine release, and STAT1 signaling with and without taurine treatment or IL-35 neutralization. An OVA-induced AR mouse model was administered vehicle, taurine, or taurine plus an IL-35 neutralizing antibody and assayed for sneezing frequency, inflammatory cytokine response, nasal mucosa goblet cell density, and T regulatory cell percentage. CD4+ cells were further examined for cytokine release, STAT1 phosphorylation, and response to an anti-IL-35 antibody with and without a STAT1 inhibitor. Results Comparison of blood from normal donors and AR patients showed a reduction in CD4+CD25+FoxP3+ Treg cells in AR patients and a strong correlation between Treg percentage and IL-35 release. A similar pattern of Treg suppression was found in untreated AR mice when compared to normal control mice wherein there was a reduction in Treg percentage and a corresponding decrease in IL-35 release. AR mice also demonstrated increased sneezing frequency, an infiltration of goblet cell in nasal mucosa, and a reduction in IL-35 release from CD4+ cells. Conversely, IL-4, IL-5, and IL-13 secretion from CD4+ cells were increased in AR model mice, as was STAT1 phosphorylation. When AR mice were treated with taurine, sneezing frequency and nasal mucosa goblet cell content were reduced while Treg abundance was increased to that of normal mice. Accordingly, IL-35 release was restored, while IL-4, IL-5, and IL-13 secretion from CD4+ cells were suppressed. Likewise, STAT1 phosphorylation was inhibited with taurine treatment. Taurine-treated mice also given an IL-35 neutralizing antibody exhibited AR pathology including frequent sneezing and high nasal goblet cell content while retaining a restoration of Tregs. Furthermore, murine AR model CD4+ cells exposed to recombinant IL-35 responded with a reduction in inflammatory cytokine release and a decrease in STAT1 phosphorylation, mimicking the effect of taurine treatment. Conclusions Taurine induces release of IL-35 in AR; IL-35 promotes the production of CD4+CD25+FoxP3+ Treg cells via a STAT1-dependent pathway. The restoration of Treg populations by taurine normalizes the inflammatory response, reduces AR symptomology, and reduces histopathologic signs of AR. Supplementary Information The online version contains supplementary material available at 10.1186/s13223-021-00562-1.
Collapse
|
6
|
Lei Y, Guo P, An J, Guo C, Lu F, Liu M. Identification of pathogenic genes and upstream regulators in allergic rhinitis. Int J Pediatr Otorhinolaryngol 2018; 115:97-103. [PMID: 30368403 DOI: 10.1016/j.ijporl.2018.09.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 09/12/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND Allergic rhinitis (AR) is the main cause of irreversible blindness in older individuals. Our study aims to identify the key genes and upstream regulators in AR. METHODS To screen pathogenic genes of AR, an integrated analysis was performed by using the microarray datasets in AR derived from the Gene Expression Omnibus (GEO) database. The functional annotation and potential pathways of differentially expressed genes (DEGs) were further discovered by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. We constructed the AR-specific transcriptional regulatory network to find the crucial transcriptional factors (TFs) which target the DEGs in AR. Electronic validation was performed to verify the DEGs obtained by integrated analysis. RESULTS From two GEO datasets obtained, we identified 793 DEGs (460 up-regulated and 333 down-regulated genes) between AR and normal control (NC). After GO and KEGG analysis, chronic inflammatory response and MAPK signaling pathway were significantly enriched pathways for DEGs. The expression of 6 genes (CLC, CST1, CRTAM, ILK, STAT1, and POSTN) was detected. The 6 genes in GEO: GSE51392 dataset played the same pattern with that in our integrated analysis. CONCLUSIONS The dysregulation of 3 genes (CST1, CLC and STAT1) may be involved in the pathogenesis of AR. AP-1 was associated with AR by regulating CST1 and CLC. Our finding can contribute to developing new potential biomarkers, revealing the underlying pathogenesis, and further raising new therapeutic targets for AR.
Collapse
Affiliation(s)
- Yanhua Lei
- Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, China
| | - Ping Guo
- Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, China
| | - Jun An
- Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, China
| | - Chao Guo
- Department of Anesthesiology, The First People's Hospital of Jining, China
| | - Fengxiang Lu
- Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, China
| | - Minglei Liu
- Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, China.
| |
Collapse
|
7
|
Gusareva ES, Kurey I, Grekov I, Lipoldová M. Genetic regulation of immunoglobulin E level in different pathological states: integration of mouse and human genetics. Biol Rev Camb Philos Soc 2013; 89:375-405. [DOI: 10.1111/brv.12059] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2012] [Revised: 06/14/2013] [Accepted: 07/31/2013] [Indexed: 12/22/2022]
Affiliation(s)
- Elena S. Gusareva
- Institute of Molecular Genetics; Academy of Sciences of the Czech Republic; Prague 4 Czech Republic
| | - Iryna Kurey
- Institute of Molecular Genetics; Academy of Sciences of the Czech Republic; Prague 4 Czech Republic
| | - Igor Grekov
- Institute of Molecular Genetics; Academy of Sciences of the Czech Republic; Prague 4 Czech Republic
| | - Marie Lipoldová
- Institute of Molecular Genetics; Academy of Sciences of the Czech Republic; Prague 4 Czech Republic
| |
Collapse
|
8
|
Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam. Clin Microbiol Rev 2010; 23:442-66. [PMID: 20375361 DOI: 10.1128/cmr.00044-09] [Citation(s) in RCA: 166] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The potential impact of the Three Gorges Dam (TGD) on schistosomiasis transmission in China has invoked considerable global concern. The TGD will result in changes in the water level and silt deposition downstream, favoring the reproduction of Oncomelania snails. Combined with blockages of the Yangtze River's tributaries, these changes will increase the schistosomiasis transmission season within the marshlands along the middle and lower reaches of the Yangtze River. The changing schistosome transmission dynamics necessitate a comprehensive strategy to control schistosomiasis. This review discusses aspects of the epidemiology and transmission of Schistosoma japonicum in China and considers the pathology, clinical outcomes, diagnosis, treatment, immunobiology, and genetics of schistosomiasis japonica together with an overview of current progress in vaccine development, all of which will have an impact on future control efforts. The use of synchronous praziquantel (PZQ) chemotherapy for humans and domestic animals is only temporarily effective, as schistosome reinfection occurs rapidly. Drug delivery requires a substantial infrastructure to regularly cover all parts of an area of endemicity. This makes chemotherapy expensive and, as compliance is often low, a less than satisfactory control option. There is increasing disquiet about the possibility that PZQ-resistant schistosomes will develop. Consequently, as mathematical modeling predicts, vaccine strategies represent an essential component in the future control of schistosomiasis in China. With the inclusion of focal mollusciciding, improvements in sanitation, and health education into the control scenario, China's target of reducing the level of schistosome infection to less than 1% by 2015 may be achievable.
Collapse
|
9
|
Chiba Y, Todoroki M, Misawa M. Phosphorylation of signal transducer and activator of transcription 6 (STAT6) and STAT1, but not STAT3, induced by antigen inhalation in bronchial smooth muscles of sensitized mice. Biol Pharm Bull 2010; 33:146-9. [PMID: 20045954 DOI: 10.1248/bpb.33.146] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The signal transducer and activator of transcription (STAT) family of molecules play a critical role in the signaling of many cytokines. In addition to STAT6, implication of STAT1 and STAT3 in the development of airway hyperresponsiveness (AHR) has also been suggested in allergic bronchial asthma. However, there is little information whether or not antigen challenge really causes the in vivo activation of these STAT molecules in bronchial smooth muscles (BSMs). In the present study, the activations of these STATs were examined in BSMs of mice with allergic bronchial asthma. Male BALB/c mice were sensitized and repeatedly challenged with ovalbumin (OA) antigen. Total protein samples of the left main bronchi were prepared at 3 after the last OA challenge, and Western blot analyses for total and tyrosine-phosphorylated STATs molecules were conducted. In addition to the phosphorylation of STAT6, a significant increase in the level of phosphorylated STAT1 was also observed after the antigen exposure. In contrast, no significant increase in the level of phosphorylated STAT3 was observed in this mouse model of allergic bronchial asthma. The antigen exposure did not change the protein expressions of these STATs themselves. These findings suggest that STAT6 and STAT1, but not STAT3, might be crucial signal transducers in the development of BSM hyperresponsiveness, one of the causes of AHR in asthmatics.
Collapse
Affiliation(s)
- Yoshihiko Chiba
- Department of Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan.
| | | | | |
Collapse
|
10
|
Chiba Y, Todoroki M, Misawa M. Activation of signal transducer and activator of transcription factor 1 by interleukins-13 and -4 in cultured human bronchial smooth muscle cells. J Smooth Muscle Res 2010; 45:279-88. [PMID: 20093796 DOI: 10.1540/jsmr.45.279] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The family of signal transducer and activator of transcription (STAT) factors play a critical role in the signaling of many cytokines. In addition to the involvement of STAT6 in allergic bronchial asthma, both STAT1 and STAT3 have also been implicated. However, there is little information whether or not the T helper 2 cytokines, which cause several key features of allergic asthma, really induce the activation of STAT1 and/or STAT3 in bronchial smooth muscle (BSM) cells. In the present study, the effects of interleukin-13 (IL-13) and IL-4 on activation of these STAT molecules were examined in cultured human bronchial smooth muscle cells (hBSMCs). After a starvation period, the hBSMCs were treated with 100 ng/ml of IL-13 or IL-4. Total protein samples were prepared at intervals of 1, 3, 6, 12 and 24 hours after the cytokine treatment, and Western blot analyses for total and tyrosine-phosphorylated STATs molecules were conducted. As a result, ut was found that both IL-13 and IL-4 caused a significant increase in the levels of phosphorylated STAT1. Examination of the time-course revealed a peak of STAT1 phosphorylation at 1 hr after cytokine application. In contrast, neither IL-13 nor IL-4 induced phosphorylation of STAT3. Neither of these cytokines changed the protein expression of the STATs themselves. These findings suggest that STAT1, but not STAT3, might also be one of the crucial signal transducers in the development of BSM hyper-responsiveness, which is one of the causes of AHR in asthmatics.
Collapse
Affiliation(s)
- Yoshihiko Chiba
- Department of Pharmacology, School of Pharmacy, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan.
| | | | | |
Collapse
|
11
|
Chiba Y, Todoroki M, Misawa M. Antigen exposure causes activations of signal transducer and activator of transcription 6 (STAT6) and STAT1, but not STAT3, in lungs of sensitized mice. Immunopharmacol Immunotoxicol 2010; 33:43-8. [PMID: 20233024 DOI: 10.3109/08923971003699026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The signal transducer and activator of transcription (STAT) family of molecules play a critical role in the signaling of many cytokines. In addition to STAT6, implication of STAT1 and STAT3 in the pathogenesis of allergic airway diseases has also been suggested. However, there is little information whether or not antigen challenge to sensitized animals causes the in vivo activation of STAT1 and/or STAT3 in the airways. In the present study, the activations of these STAT molecules were monitored in lungs of mice with allergic bronchial asthma. Male BALB/c mice were sensitized and repeatedly challenged with ovalbumin (OA) antigen. Total protein samples of lungs were prepared at ∼1-24 h after the last OA challenge, and western blot analyses for total and tyrosine-phosphorylated STATs (pSTATs) molecules were conducted. In addition to the phosphorylation of STAT6, STAT1 was also phosphorylated in lungs after the inhalation of OA antigen. Both the phosphorylation of STAT6 and STAT1 occurred at the early stage after the antigen exposure. In contrast, no significant increase in the level of pSTAT3 was observed in this mouse model of allergic bronchial asthma. In conclusion, the current findings suggest that STAT6 and STAT1, but not STAT3, might be crucial signal transducers in the pathogenesis of allergic bronchial asthma.
Collapse
Affiliation(s)
- Yoshihiko Chiba
- Department of Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan.
| | | | | |
Collapse
|
12
|
Mouse models of allergic diseases. Curr Opin Immunol 2009; 21:660-5. [PMID: 19828303 DOI: 10.1016/j.coi.2009.09.005] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2009] [Accepted: 09/01/2009] [Indexed: 12/11/2022]
Abstract
The increasing prevalence of allergic diseases worldwide is posing significant socio-economic challenges. The pathogenesis of these diseases reflects a complex interaction of genetic and environmental factors. The heterogeneity of disease phenotypes challenges the concept of single mechanisms of disease. As human experimentation is limited, animal models have been developed to provide insights into pathogenesis and potential for discovery of novel therapeutics. Mice have served in models of many of the allergic diseases including asthma, allergic rhinitis, food allergy, atopic dermatitis (AD), and allergic conjunctivitis. Although much has been learned from these investigations, there are limitations when these models are translated to the human diseases.
Collapse
|